Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0NUFGJ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
aU2023308528A1 ADC3
|
|||||
| Synonyms |
AU2023308528A1 ADC3
Click to Show/Hide
|
|||||
| Organization |
PHEON THERAPEUTICS LTD
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
7.3
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mal-amido-PEG8-acid
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
1- (3- (2,5-dioxo-2,5-dihydro-1h-pyrrol-1-yl)propanamido)-n- ((2s)-1- (( (2s)-1 (( (1s,9s)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,12,13,13a,14 octahydro-1h-benzo[de]pyrano[3',4':6,7]indeno[1,2-b]quinolin-1-yl)amino)-1 oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-3,6,9,12,15,18,21,24 octaoxaheptacosan-27-amide
|
|||||
General Information of The ADMET Data Related to This ADC(2027 Update)
Excretion
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Elimination Half-Life (t1/2) | 182 | hr |
Half-life of 10 mg/kg ADC3 was compared to the same concentration of unconjugated antibody, with male CD-1 mice being administered a single dose of each and plasma concentration being measured daily. Time lasted even 7 days.
Click to Show/Hide
|
[1] |
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 30% | |||
| Method Description |
ADC3 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model at 6 mg/kg single doses and was found to reduce the rate of tumor growth compared to vehicle
|
||||
| In Vivo Model | MDA-MB-231 Xenograft Model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 60% | |||
| Method Description |
ADC3 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model at 10 mg/kg single doses and was found to reduce the rate of tumor growth compared to vehicle
|
||||
| In Vivo Model | MDA-MB-231 Xenograft Model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 60% | |||
| Method Description |
ADC3 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model after three doses at 10 mg/kg was found to reduce the rate of tumor growth compared to vehicle
|
||||
| In Vivo Model | MDA-MB-231 Xenograft Model | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 80% | |||
| Method Description |
ADC3 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model after three doses at 6 mg/kg was found to reduce the rate of tumor growth compared to vehicle
|
||||
| In Vivo Model | MDA-MB-231 Xenograft Model | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 90% | |||
| Method Description |
ADC3 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model after three doses at 3 mg/kg was found to reduce the rate of tumor growth compared to vehicle
|
||||
| In Vivo Model | MDA-MB-231 Xenograft Model | ||||